SCP
TSHA icon

Sender Company & Partners’s Taysha Gene Therapies TSHA Stock Holding History

Sender Company & Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-27,121
Closed -$88.7K – 423
2025
Q3 		$88.7K Buy
+27,121
New +$76.8K 0.01% 445

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sender Company & Partners's TSHA Position: Q4 2025 in Review

Sender Company & Partners sold out of Taysha Gene Therapies (TSHA) in Q4 2025, closing a stake of 27,121 shares — an estimated $88.7K sold.

Sender Company & Partners first reported a position in TSHA in Q3 2025 and held it in 1 quarter. The position peaked at $88.7K in Q3 2025. 195 funds tracked by Wall St. Rank hold TSHA as of Q4 2025.

  • Sender Company & Partners reported no remaining Taysha Gene Therapies position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 27,121 Taysha Gene Therapies shares in Q4 2025, an estimated $88.7K.
  • Sender Company & Partners first reported a position in Taysha Gene Therapies in Q3 2025 and held it in 1 quarter.
  • Sender Company & Partners's Taysha Gene Therapies position peaked at $88.7K in Q3 2025.
  • 195 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.